Jiaozuo Bio-Tech (Sino-Canadian Joint Venture) Co., Ltd.
Release time:
2026-06-05
Jiaozuo Bio‑Tech (Sino‑Canadian Joint Venture) Biotechnology Co., Ltd. (“BIOTECH”) is a high‑tech company dedicated to the research, development, and commercialization of biotechnological innovations. Established in 2013 and officially registered in 2015, the company is headquartered in Wuzhi County, Jiaozuo City, Henan Province, and serves as BIOTECH’s Chinese joint venture with Canada. BIOTECH has forged strong collaborative ties with the University of Alberta, focusing on the R&D of rapid immunological diagnostic reagents and equipment. The company boasts unique strengths in areas such as food microbiology, detection of illegal additives, veterinary drug residues, mycotoxin analysis, animal disease diagnostics, and antibody‑level monitoring. Leveraging technologies in cell engineering, molecular biology, and immunology, BIOTECH employs a comprehensive process—“artificial antigen synthesis → animal immunization → cell culture → antibody screening → monoclonal antibody production → kit assembly → stability testing → packaging → finished product”—to develop and manufacture a range of innovative, proprietary immunological rapid‑detection products, including biological mono‑ and polyclonal antibodies, colloidal gold test strips, and ELISA kits. Compared with instrumental methods such as HPLC, LC‑ECD, LC‑FLD, LC‑UV, and LC‑MS, these products offer advantages including ease of use, affordability, short assay times, high sensitivity, robust performance, and excellent practicality, ensuring promising market prospects and significant social benefits. BIOTECH currently employs over 22 staff members, 16 of whom hold graduate degrees or higher, including one doctoral candidate; more than 70% of the workforce holds master’s degrees or above. Over 50% of the team are full‑time technical developers, spanning disciplines such as veterinary medicine, animal nutrition and feed science, microbiology, food science, analytical chemistry, immunology, and molecular biology. Key members of the company’s technical team have participated in or led numerous national science and technology projects funded by the National Natural Science Foundation, holding 18 national patents and having published more than ten SCI‑indexed papers, thereby establishing a distinct competitive edge in the field of rapid immunological diagnostic reagent development. The BIOTECH R&D center covers an area of 1,000 square meters and is equipped with specialized facilities, including a cell engineering lab, an antibody testing lab, a sterile room, a molecular biology lab, and a P2 biosafety laboratory. It houses over 40 pieces of cutting‑edge research equipment, such as microplate readers, gel electrophoresis imaging systems, liquid chromatography instruments, clean benches, autoclaves, dot‑blot printers, high‑speed refrigerated centrifuges, UV scanners, liquid nitrogen tanks, CO₂ incubators, and inverted microscopes. By fully leveraging industry–university–research collaboration and its talented workforce, BIOTECH places rapid immunodiagnostic technology at the core of its innovation efforts, deeply exploring and developing a series of advanced products aimed at providing customers with comprehensive, end‑to‑end solutions. Adhering to the corporate mission of “scientific rigor, fairness and impartiality, speed and accuracy, and trustworthy service,” BIOTECH maintains a meticulous work ethic, standardized operational procedures, and high‑quality service standards. Guided by market demand and driven by industrialization, the company relies on independent innovation and uncompromising quality to accelerate progress in food safety and disease diagnosis and testing, delivering more holistic, higher‑quality services to its clients.
Jiaozuo Bio‑Tech (a Sino‑Canadian joint venture) Biotechnology Co., Ltd. (“BIOTECH”) is a high‑tech company dedicated to the research, development, and commercialization of biotechnological innovations. Established in 2013 and officially registered and launched in 2015, the company is headquartered in Wuzhi County, Jiaozuo City, Henan Province, and serves as BIOTECH’s Chinese joint venture with Canada. BIOTECH has forged a strong collaborative partnership with the University of Alberta, focusing on the R&D of rapid immunoassay reagents and related equipment. The company boasts distinctive strengths in areas such as food microbiology, detection of unauthorized additives, veterinary drug residues, mycotoxin analysis, animal disease diagnostics, and antibody‑level monitoring. Leveraging technologies in cell engineering, molecular biology, and immunology, BIOTECH employs a comprehensive process—“artificial antigen synthesis–animal immunization–cell culture–antibody screening–monoclonal antibody production–kit assembly–stability testing–packaging–final product”—to develop and manufacture a range of innovative rapid immunoassay products, including bio‑derived mono‑ and polyclonal antibodies, colloidal gold test strips, and enzyme‑linked immunosorbent assay (ELISA) kits, all underpinned by proprietary intellectual property. Compared with instrumental analyses such as HPLC, LC‑ECD, LC‑FLD, LC‑UV, and LC‑MS, these rapid diagnostic products offer advantages including ease of use, cost‑effectiveness, short assay times, high sensitivity, robust performance, and excellent practicality, thereby demonstrating promising market prospects and significant social benefits.
BIOTECH currently employs over 22 staff members, 16 of whom hold graduate degrees or higher, including one doctoral candidate. Personnel with master’s degrees or above account for more than 70% of the total workforce. Full-time technical developers comprise over 50% of the team, spanning disciplines such as veterinary medicine, animal nutrition and feed science, microbiology, food science, analytical chemistry, immunology, and molecular biology. Key members of the company’s technical team have repeatedly participated in or led numerous national science and technology projects, including those funded by the National Natural Science Foundation, and hold 18 national patents. They have also published more than ten SCI‑indexed papers and enjoy a distinct competitive edge in the development of rapid diagnostic reagents for immunology.
BIOTECH’s R&D center spans 1,000 m² and is equipped with a cell engineering lab, an antibody‑testing lab, a sterile room, a molecular biology lab, and a P2 biosafety laboratory. It houses more than 40 pieces of cutting‑edge research equipment, including microplate readers, gel‑electrophoresis imaging systems, liquid chromatographs, laminar flow hoods, autoclaves, dot‑blot printers, high‑speed refrigerated centrifuges, UV scanners, liquid nitrogen tanks, CO₂ incubators, and inverted microscopes. Leveraging the strengths of industry–university–research collaboration and its talented workforce, the company focuses on rapid immunoassay technologies, conducting in‑depth research and developing a portfolio of high‑tech products aimed at providing customers with comprehensive, end‑to‑end solutions.
The company upholds the principles of “scientific rigor, fairness and impartiality, speed and accuracy, and integrity in service,” maintaining a meticulous work ethic, standardized operating procedures, and a high standard of service. With a market‑oriented approach and an eye toward industrialization, it leverages independent innovation and uncompromising quality to drive the rapid advancement of food safety and disease‑diagnosis testing, delivering more comprehensive, higher‑quality services to its customers.
Tags:
Previous page
Next page
Previous page:
Next page:
Related Blog
Xuru Group has generously donated supplies and fulfilled its social responsibility!
Since July 20, a once-in-a-millennium torrential downpour has battered the Central Plains, with prolonged rainfall across many parts of Henan Province. Cities such as Xinxiang, Zhengzhou, and Jiaozuo have suffered severe damage. In Xinxiang, multiple rivers have breached their banks, prompting the urgent evacuation of local residents; vast areas of farmland have been submerged, disrupting the normal production and daily life of the general public and businesses alike.
2021-07-27
On the afternoon of August 19, 2021, Municipal Party Secretary Ge Qiaohong, along with city leaders Niu Yanping and Wu Lei, and county leaders Qin Yingjun and Shen Lin, paid a visit to Xuru Group for an inspection. Chairman Qiu Guoqing of the Group extended a warm welcome to Secretary Ge Qiaohong and her delegation, and expressed his heartfelt gratitude to government departments at all levels for their continued care and support of Xuru Group.
2021-11-08
Supporting epidemic prevention and control, Xuru Group’s charitable donations are ongoing.
With united resolve, we stand together to fight the epidemic, and Xuru Group actively fulfills its social responsibilities. To curb the spread of the virus and help Jiaozuo win the battle against the pandemic, the company has donated 50,000 yuan in cash to the Wuzhi Charity Association to support epidemic prevention and control efforts, and provided supplies worth 50,000 yuan to epidemic control checkpoints in Xiuwu County and Wuzhi County, thereby contributing its share to the decisive fight against the pandemic.
2023-02-18
Share to
Contact Us
Join forces for collaboration and jointly create a sustainable, high-tech agriculture and animal husbandry industry.
If you would like to learn more about our products, please feel free to contact us.
Contact Us
Manager Zhang:+86-18639100886
Phone:+86-391-7557228
Email:244902575@qq.com
Address: Dainie Village, Sanyang Township, Wuzhi County, Jiaozuo City, Henan Province
Xubairui Feed
TikTok account
Official Account
Video Account
Xuru Food
TikTok account
Official Account
Video Account